EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022
Published on December 2012

Report Summary


Summary

Dyslipidemia is a condition in which one or more blood lipid levels are abnormal. It is an underdiagnosed, undertreated, and highly
prevalent disease worldwide. Prevalent cases of dyslipidemia in the nine markets is expected to increase from 443.8 million cases in
2012 to 522.0 million cases in 2022 at the rate of 1.76% per year. Factors that influence prevalence include risk factors, disease
management, awareness of disease status, population growth, and changes in diagnosis and treatment guidelines. In 2012, India had
the highest number of prevalent dyslipidemia cases in the nine major markets at 192.7 million, followed by China at 84.7 million, and
the US at 48.6 million. These three countries will continue to dominate in the number of prevalent cases through 2022, during which
they will be expected to contribute to 65.6% of the total 522.0 million prevalent cases of all markets combined. This trend is driven
mainly by the large populations as the prevalence rates are relatively low in these countries. EU countries such as Germany, Spain,
and the UK had prevalence rates that were two or three times that of the other countries. The sex gap for dyslipidemia prevalent
cases in the nine markets is not significantly high in this analysis. However, age-group analysis showed that dyslipidemia is most
prevalent in people ages 40'69 years. The prevalence of dyslipidemia is also affected by the diagnosis and treatment guidelines
followed by each country. An update in the ATP guidelines, ATP-IV, is expected to be released at the end of 2012 or 2013 and may
impact the prevalent cases forecast.

Scope

- The dyslipidemia EpiCast Report provide an overview of the risk factors and global trends of dyslipidemia in seven major markets
(the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to two emerging markets'India and China.
- It includes a 10-year epidemiological forecast of dyslipidemia prevalence segmented by sex and age (by 5-year age groups
beginning at 20 years of age) to 2022.

Reasons to buy

- Develop business strategies by understanding the historical trends of global dyslipidemia market as well as the risk factors and
treatment and diagnosis guidelines that shape the trends.
- Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age group and gender that present the best opportunities for dyslipidemia
therapeutics in each of the markets covered.

Table of Content

Table of Contents

1 Table of Contents 4

EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022 (From Slideshare) Page 1/5


1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
3 Epidemiology 8
3.1 Disease Background and Definition 8
3.2 Common Diagnostic Criteria for Dyslipidemia 9
3.2.1 NCEP-ATPIII Guidelines 9
3.2.2 ESC/ EAS Guidelines 10
3.3 Risk Factors and Comorbidities 11
3.3.1 Sedentary Lifestyle, High Caloric and Alcohol Intake are Associated with Dyslipidemia 11
3.3.2 Sex Disparity in Dyslipidemia Treatment is Large, but the Reasons are Unclear 11
3.3.3 Dyslipidemia is a Strong Risk Factor for CVD 11
3.4 Secondary Causes of Dyslipidemia 12
3.5 Global Trends 13
3.5.1 United States 13
3.5.2 Europe 14
3.5.3 Asia 14
3.6 Forecast Methodology 15
3.6.1 Sources Used 17
3.6.2 Forecast Assumptions and Methods 21
3.7 Epidemiology Forecast (2012-2022) 25
3.7.1 Prevalent Cases of Dyslipidemia 25
3.7.2 Age-Specific Prevalent Cases of Dyslipidemia 28
3.7.3 Sex-Specific Prevalent Cases of Dyslipidemia 31
3.8 Discussion 33
3.8.1 Conclusions Regarding Epidemiological Trends 33
3.8.2 Limitations of the Analysis 34
3.8.3 Strengths of the Analysis 34
4 Appendix 35
4.1 Bibliography 35
4.2 About the Authors 41
4.2.1 Epidemiologists 41
4.2.2 Reviewers 41
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 42
4.2.4 Global Head of Healthcare 43
4.3 About GlobalData 43
4.4 About EpiCast 43
4.5 Contact Us 44
4.6 Disclaimer 44

List of Tables
Table 1: NCEP-ATP III Classification of TC, LDL-C, HDL-C, and TG (mg/dL) 10
Table 2: Nine Major Markets, Sources of Prevalent Data Used in the Epidemiology Forecast 16
Table 3: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages '20, Men and Women, N, Selected Years, 2012-2022 26



Table 4: Nine Major Markets, Prevalent Cases of Dyslipidemia, By Age*, Men and Women, N (Row %), 2012 29
Table 5: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages '20 Years, By Sex, N (Row %), 2012 31

List of Figures
Figure 1: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages '20, Men and Women, N, Select Years, 2012-2022 27
Figure 2: Nine Major Markets, Prevalent Cases of Dyslipidemia, By Age*, Men and Women, N, 2012 30
Figure 3: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages '20 Years, By Sex, N, 2012 32


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 6 995.00 Quantity: _____

Site License--USD 20 985.00 Quantity: _____

Corporate License--USD 27 980.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022